Blood Res.  2020 Mar;55(1):67-68. 10.5045/br.2020.55.1.67.

Molecular screening for an underlying myeloproliferative neoplasm in patients with stroke: who and how?

• Langabeer

• KMID: 2472012
• DOI: http://doi.org/10.5045/br.2020.55.1.67

Abstract

No abstract available.

MeSH Terms

Humans
Mass Screening*
Stroke*

Reference

1. Song IC, Choi YS, Shin JW, Song HJ, Kim J, Jo DY. Retrospective screening for Philadelphia-negative myeloproliferative neoplasms in patients with cerebral infarctions as revealed using the revised 2016 World Health Organization diagnostic criteria. Blood Res. 2019; 54:284–285. PMID: 31915656.

2. GBD 2016 Lifetime Risk of Stroke Collaborators. Global, regional, and country-specific lifetime risks of stroke, 1990 and 2016. N Engl J Med. 2018; 379:2429–2437. PMID: 30575491.

3. Economides MP, Verstovsek S, Pemmaraju N. Novel therapies in myeloproliferative neoplasms (MPN): beyond JAK inhibitors. Curr Hematol Malig Rep. 2019; 14:460–468. PMID: 31372878.

4. Anderson N, Bonsell K. Ischemic stroke as the presenting symptom in a young patient with essential thrombocythemia caused by CALR gene mutation. Neurology (AAN 67th Annual Meeting Abstracts. 2015; 84(Suppl):abst P2.253.

5. Beer PA, Campbell PJ, Scott LM, et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood. 2008; 112:141–149. PMID: 18451306.

6. Pietra D, Li S, Brisci A, et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood. 2008; 111:1686–1689. PMID: 17984312.

7. Stefanou MI, Richter H, Härtig F, et al. Recurrent ischaemic cerebrovascular events as presenting manifestations of myeloproliferative neoplasms. Eur J Neurol. 2019; 26:903–e64. PMID: 30629793.